Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

References

• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–17. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, Bendahman N, Hammers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–48. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Barelle C, Porter A. Vnars: an ancient and unique repertoire of molecules that deliver small, soluble, stable and high affinity binders of proteins. Antibod. 2015;4(3):240–58. doi:10.3390/antib4030240.
   Google Scholar
• Muyldermans S, Atarhouch T, Saldanha J, Barbosa JARG, Hamers R. Sequence and structure of V H domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng Des Sel. 1994;7(9):1129–35. doi:10.1093/protein/7.9.1129.
   Google Scholar
• Spinelli S, Frenken L, Bourgeois D, De Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegonil M. The crystal structure of a llama heavy chain variable domain. Nat Struct Mol Biol. 1996;3(9):752–57. doi:10.1038/nsb0996-752.
   Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775–97. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• Li X, Duan X, Yang K, Zhang W, Zhang C, Fu L, Ren Z, Wang C, Wu J, Lu R. et al. Comparative analysis of immune repertoires between bactrian camel’s conventional and heavy-chain antibodies. PloS One. 2016;11(9):e0161801. doi:10.1371/journal.pone.0161801.
   PubMed Web of Science ®Google Scholar
• Tu Z, Huang X, Fu J, Hu N, Zheng W, Li Y, Zhang Y. Landscape of variable domain of heavy‐chain‐only antibody repertoire from alpaca. Immunology. 2020;161(1):53–65. doi:10.1111/imm.13224.
   PubMed Web of Science ®Google Scholar
• Olsen TH, Boyles F, Deane CM. Observed antibody space: a diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 2022;31(1):141–46. doi:10.1002/pro.4205.
   PubMed Web of Science ®Google Scholar
• Gordon GL, Capel HL, Guloglu B, Richardson E, Stafford RL, Deane CM. A comparison of the binding sites of antibodies and single-domain antibodies. Front Immunol. 2023;14:1231623. doi:10.3389/fimmu.2023.1231623.
   PubMed Web of Science ®Google Scholar
• Vattekatte AM, Shinada NK, Narwani TJ, Noël F, Bertrand O, Meyniel J-P, Malpertuy A, Gelly J-C, Cadet F, de Brevern AG. Discrete analysis of camelid variable domains: sequences, structures, and in-silico structure prediction. PeerJ. 2020;8:e8408. doi:10.7717/peerj.8408.
   PubMed Web of Science ®Google Scholar
• Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire. Embo J. 2000;19(5):921–30. doi:10.1093/emboj/19.5.921.
   PubMed Web of Science ®Google Scholar
• Mendoza MN, Jian M, King MT, Brooks CL. Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the listeria virulence factor InlB. Protein Sci. 2020;29(4):990–1003. doi:10.1002/pro.3831.
   Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, Vrieze SD, Serruys B, Ulrichts H, Vandevelde W. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107(47):20565–70. doi:10.1073/pnas.1012865107.
   PubMed Web of Science ®Google Scholar
• Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, Webb D, MacDougall M, Kerr S, Berger V. et al. VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. Mabs-austin. 2020;12(1):1709322. doi:10.1080/19420862.2019.1709322.
   PubMed Web of Science ®Google Scholar
• Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature. 2013;502(7472):575–79. doi:10.1038/nature12572.
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Bilofsky H. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J Biol Chem. 1977;252(19):6609–16. doi:10.1016/S0021-9258(17)39891-5.
   PubMed Web of Science ®Google Scholar
• Soler MA, Medagli B, Wang J, Oloketuyi S, Bajc G, Huang H, Fortuna S, de Marco A. Effect of humanizing mutations on the stability of the llama single-domain variable region. Biomolecules. 2021;11(2):163. doi:10.3390/biom11020163.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Transue TR, Gharoudi MA, Thi MD, Poortmans F, Hamers R, Muyldermans S, Wyns L. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nature Struct Molecul Biol. 1997;3(9):803–11. doi:10.1038/nsb0996-803.
   Google Scholar
• Bond CJ, Marsters JC, Sidhu SS. Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries. J Mol Biol. 2003;332(3):643–55. doi:10.1016/S0022-2836(03)00967-7.
   PubMed Web of Science ®Google Scholar
• Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, Wiesmann C, Sidhu SS. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem. 2008;283(6):3639–54. doi:10.1074/jbc.M708536200.
   PubMed Web of Science ®Google Scholar
• Rouet R, Dudgeon K, Christie M, Langley D, Christ D. Fully human VH single domains that rival the stability and cleft recognition of camelid antibodies. J Biol Chem. 2015;290(19):11905–17. doi:10.1074/jbc.M114.614842.
   PubMed Web of Science ®Google Scholar
• Riechmann L, Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods. 1999;231(1–2):25–38. doi:10.1016/S0022-1759(99)00138-6.
   PubMed Web of Science ®Google Scholar
• Tanha J, Nguyen T-D, Ng A, Ryan S, Ni F, MacKenzie R. Improving solubility and refolding efficiency of human VHs by a novel mutational approach. Protein Eng Des Sel. 2006;19(11):503–09. doi:10.1093/protein/gzl037.
   PubMed Web of Science ®Google Scholar
• van der Linden RHJ, Frenken LGJ, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1999;1431(1):37–46. doi:10.1016/S0167-4838(99)00030-8.
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco MS, Valdés-Tresanco ME, Molina-Abad E, Moreno E. NbThermo: a new thermostability database for nanobodies. Database. 2023;2023:baad021. doi:10.1093/database/baad021.
   PubMedGoogle Scholar
• Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid V HH domains compared to those of human V H 3 domains. Biochem. 2002;41(11):3628–36. doi:10.1021/bi011239a.
   PubMed Web of Science ®Google Scholar
• Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal Chem. 2006;78(13):4501–08. doi:10.1021/ac058044j.
   PubMed Web of Science ®Google Scholar
• Kunz P, Zinner K, Mücke N, Bartoschik T, Muyldermans S, Hoheisel JD. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci Rep. 2018;8(1):7934. doi:10.1038/s41598-018-26338-z.
   PubMedGoogle Scholar
• Zimmermann I, Egloff P, Hutter CA, Arnold FM, Stohler P, Bocquet N, Hug MN, Huber S, Siegrist M, Hetemann L. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife. 2018;7:e34317. doi:10.7554/eLife.34317.
   PubMed Web of Science ®Google Scholar
• Moreno E, Valdés-Tresanco MS, Molina-Zapata A, Sánchez-Ramos O. Structure-based design and construction of a synthetic phage display nanobody library. BMC Res Notes. 2022;15(1):124. doi:10.1186/s13104-022-06001-7.
   PubMed Web of Science ®Google Scholar
• Murakami T, Kumachi S, Matsunaga Y, Sato M, Wakabayashi-Nakao K, Masaki H, Yonehara R, Motohashi M, Nemoto N, Tsuchiya M. Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics. Antibod. 2022;11(1):10. doi:10.3390/antib11010010.
   Web of Science ®Google Scholar
• Kinoshita S, Nakakido M, Mori C, Kuroda D, Caaveiro JMM, Tsumoto K. Molecular basis for thermal stability and affinity in a VHH: contribution of the framework region and its influence in the conformation of the CDR3. Protein Sci. 2022;31(11):e4450. doi:10.1002/pro.4450.
   PubMed Web of Science ®Google Scholar
• Klarenbeek A, Mazouari KE, Desmyter A, Blanchetot C, Hultberg A, de Jonge JN, Roovers RC, Cambillau C, Spinelli S, Del-Favero J. et al. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. Mabs-austin. 2015;7(4):693–706. doi:10.1080/19420862.2015.1046648.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, Baetselier PD, Muyldermans S, Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004;64(8):2853–57. doi:10.1158/0008-5472.CAN-03-3935.
   PubMed Web of Science ®Google Scholar
• Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, de Wiele CV, Staelens L. et al. Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis & Rheumatism. 2006;54(6):1856–66. doi:10.1002/art.21827.
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284(5):3273–84. doi:10.1074/jbc.M806889200.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C. et al. Pre-existing antibody: biotherapeutic modality-based review. Aaps J. 2016;18(2):311–20. doi:10.1208/s12248-016-9878-1.
   PubMed Web of Science ®Google Scholar
• van Schie KA, Wolbink G-J, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies—effects on treatment and immunogenicity. Mabs-austin. 2015;7(4):662–71. doi:10.1080/19420862.2015.1048411.
   PubMed Web of Science ®Google Scholar
• Rossotti MA, Bélanger K, Henry KA, Tanha J. Immunogenicity and humanization of single‐domain antibodies. FEBS J. 2022;289(14):4304–27. doi:10.1111/febs.15809.
   PubMed Web of Science ®Google Scholar
• Lin J, Lee SL, Russell AM, Huang RF, Batt MA, Chang SS, Ferrante A, Verdino P, Henry KA. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PloS One. 2021;16(7):e0254944. doi:10.1371/journal.pone.0254944.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim I, Zheng L, Vernes J-M, Meng YG, Spiess C. Evading pre-existing anti-hinge antibody binding by hinge engineering. Mabs-austin. 2016;8(8):1536–47. doi:10.1080/19420862.2016.1219006.
   PubMed Web of Science ®Google Scholar
• Cordy JC, Morley PJ, Wright TJ, Birchler MA, Lewis AP, Emmins R, Chen YZ, Powley WM, Bareille PJ, Wilson R. et al. Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1. Clin Exp Immunol. 2015;182(2):139–48. doi:10.1111/cei.12680.
   PubMed Web of Science ®Google Scholar
• Salema V, Fernández LÁ. High yield purification of nanobodies from the periplasm of E. coli as fusions with the maltose binding protein. Protein Express Purificat. 2013;91(1):42–48. doi:10.1016/j.pep.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Kariuki CK, Magez S. Improving the yield of recalcitrant nanobodies® by simple modifications to the standard protocol. Protein Expr Purif. 2021;185:105906. doi:10.1016/j.pep.2021.105906.
   PubMed Web of Science ®Google Scholar
• Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antibody Ther. 2021;4(2):73–88. doi:10.1093/abt/tbab007.
   PubMedGoogle Scholar
• Viardot A, Goebeler M-E, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–16. doi:10.1182/blood-2015-06-651380.
   PubMed Web of Science ®Google Scholar
• Guo R, Meng X, Wang F, Yu J, Xie Q, Zhao W, Zhu L, Kung HF, Yang Z, Li N. 68Ga-P15-041, a novel bone imaging agent for diagnosis of bone metastases. Front Oncol. 2021;11:766851. doi:10.3389/fonc.2021.766851.
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LOT, Caveliers V, Vanhove C, Keyaerts M, Baetselier PD, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10(3):167–75. doi:10.1007/s11307-008-0133-8.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S. et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding*. J Biol Chem. 2014;289(19):13492–502. doi:10.1074/jbc.M114.549832.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. A guide to: generation and design of nanobodies. The FEBS J. 2021;288(7):2084–102. doi:10.1111/febs.15515.
   PubMed Web of Science ®Google Scholar
• Kovaltsuk A, Leem J, Kelm S, Snowden J, Deane CM, Krawczyk K. Observed antibody space: a resource for data mining next-generation sequencing of antibody repertoires. J Immunol. 2018;201(8):2502–09. doi:10.4049/jimmunol.1800708.
   PubMed Web of Science ®Google Scholar
• Deszyński P, Młokosiewicz J, Volanakis A, Jaszczyszyn I, Castellana N, Bonissone S, Ganesan R, Krawczyk K. INDI—integrated nanobody database for immunoinformatics. Nucleic Acids Res. 2022;50(D1):D1273–81. doi:10.1093/nar/gkab1021.
   PubMed Web of Science ®Google Scholar
• Abanades B, Olsen TH, Raybould MIJ, Aguilar-Sanjuan B, Wong WK, Georges G, Bujotzek A, Deane CM. The patent and literature antibody database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures. Nucleic Acids Res. 2024;52(D1):D545–51. doi:10.1093/nar/gkad1056.
   PubMedGoogle Scholar
• Contreras MA, Serrano-Rivero Y, González-Pose A, Salazar-Uribe J, Rubio-Carrasquilla M, Soares-Alves M, Parra NC, Camacho-Casanova F, Sánchez-Ramos O, Moreno E. Design and construction of a synthetic nanobody library: testing its potential with a single selection round strategy. Molecules. 2023;28(9):3708. doi:10.3390/molecules28093708.
   PubMed Web of Science ®Google Scholar
• Shin J-E, Riesselman AJ, Kollasch AW, McMahon C, Simon E, Sander C, Manglik A, Kruse AC, Marks DS. Protein design and variant prediction using autoregressive generative models. Nat Commun. 2021;12(1):2403. doi:10.1038/s41467-021-22732-w.
   PubMed Web of Science ®Google Scholar
• de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM. et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. OncoImmunol. 2018;7(1):e1375641. doi:10.1080/2162402X.2017.1375641.
   Web of Science ®Google Scholar
• Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD. et al. Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor. Cancers. 2021;13(21):5446. doi:10.3390/cancers13215446.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Cuesta AM, Blanco-Toribio A, Harwood SL, Villate M, Merino N, Bonet J, Navarro R. et al. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Sci Rep. 2016;6(1):28643. doi:10.1038/srep28643.
   PubMedGoogle Scholar
• Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, En Henegouwen PMPVB, Lykkemark S. et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunol. 2018;7(1):e1377874. doi:10.1080/2162402X.2017.1377874.
   Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall’acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep-Uk. 2017;7(1):40098. doi:10.1038/srep40098.
   PubMedGoogle Scholar
• Dicara DM, Bhakta S, Go MA, Ziai J, Firestein R, Forrest B, Gu C, Leong SR, Lee G, Yu S-F. et al. Development of T-cell engagers selective for cells co-expressing two antigens. Mabs-austin. 2022;14(1):2115213. doi:10.1080/19420862.2022.2115213.
   PubMed Web of Science ®Google Scholar
• Tapia-Galisteo A, Rodríguez ÍS, Aguilar-Sopeña O, Harwood SL, Narbona J, Gutierrez MF, Navarro R, Martín-García L, Corbacho C, Compte M. et al. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. Oncoimmunol. 2022;11(1):2034355. doi:10.1080/2162402X.2022.2034355.
   PubMed Web of Science ®Google Scholar
• Ridgway JBB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9(7):617–21. doi:10.1093/protein/9.7.617.
   Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677–81. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H. et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015;290(12):7535–62. doi:10.1074/jbc.M114.620260.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Decker PD, Tersteeg C, Canvin J, Callewaert F, Winter HD. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Expert Rev Clin Pharmacol. 2019;12(6):537–45. doi:10.1080/17512433.2019.1607293.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, Sato Y, Uchida S, Tanaka Y. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1):60. doi:10.1186/s13075-023-03036-4.
   PubMedGoogle Scholar
• Ortiz S, McEneny A, Amancha P, Rice K, Scholz J, Rakhade S, Yee M. Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a phase 1, randomized, double-blind, placebocontrolled, single and multiple ascending dose study (P1-5.016). Neurology. 2023;100(17_supplement_2):100. doi:10.1212/WNL.0000000000203482.
   Web of Science ®Google Scholar
• Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019;81(1):196–203. doi:10.1016/j.jaad.2019.03.056.
   PubMed Web of Science ®Google Scholar
• Hofmann I, Baum A, Hofmann MH, Trapani F, Reichel-Voda C, Ehrensperger D, Aichinger M, Ebner F, Budano N, Schweifer N. et al. Pharmacodynamic and antitumor activity of BI 836880, a dual vascular endothelial growth factor and angiopoietin 2 inhibitor, alone and combined with programmed cell death protein-1 inhibition. J Pharmacol Exp Ther. 2023;384(3):331–42. doi:10.1124/jpet.122.001255.
   PubMed Web of Science ®Google Scholar
• Tourneau CL, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G. et al. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 2022;7(5):100576. doi:10.1016/j.esmoop.2022.100576.
   PubMed Web of Science ®Google Scholar
• Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, Taeye SD, den Heede HK, Roobrouck A, Grot E, Kent TC. et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol. 2015;87(2):251–62. doi:10.1124/mol.114.094821.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y, Yang Y, Fang W, Guo Y, Li Q, Ge X. et al. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J Immunother Cancer. 2023;11(6):e006654. doi:10.1136/jitc-2022-006654.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Dy GK, Mamdani H, Dowlati A, Schoenfeld AJ, Pacheco JM, Sanborn RE, Menon SP, Santiago L, Yaron Y. et al. Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. J Clin Oncol. 2022;40(16_suppl):8566–8566. doi:10.1200/JCO.2022.40.16_suppl.8566.
   Web of Science ®Google Scholar
• Molloy ME, Austin RJ, Lemon BD, Aaron WH, Ganti V, Jones A, Jones SD, Strobel KL, Patnaik P, Sexton K. et al. Preclinical characterization of HPN536, a trispecific, T-Cell–activating protein construct for the treatment of mesothelin-expressing solid tumors. Clin Cancer Res. 2021;27(5):1452–62. doi:10.1158/1078-0432.CCR-20-3392.
   PubMed Web of Science ®Google Scholar
• Hsieh EM, Rouce RH. Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. Hematology. 2020;2020(1):487–93. doi:10.1182/hematology.2020000133.
   PubMedGoogle Scholar
• Lameris R, Shahine A, Pellicci DG, Uldrich AP, Gras S, Nours JL, Groen RWJ, Vree J, Reddiex SJJ, Quiñones-Parra SM. et al. A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. Nat Cancer. 2020;1(11):1054–65. doi:10.1038/s43018-020-00111-6.
   PubMedGoogle Scholar
• Kater AP, Donk NWCJVD, Rodríguez-Otero P, Mateos MV, Bosch F, Tucci A, Ghia P, Adang AEP, Parren PWHI, Tuinhof I. et al. Lava-051, a novel bispecific gamma-Delta T-cell engager (Gammabody), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data. Blood. 2022;140(Supplement 1):4608–09. doi:10.1182/blood-2022-166851.
   Google Scholar
• Mehra N, Robbrecht D, Voortman J, Parren PW, Macia S, Veeneman J, Umarale S, Winograd B, Vliet HJ, van der Wise DR. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). J Col. 2023;41(6_suppl):153–153. doi:10.1200/JCO.2023.41.6_suppl.153.
   Google Scholar
• Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016;22(14):3440–50. doi:10.1158/1078-0432.CCR-15-2710.
   PubMed Web of Science ®Google Scholar
• Felices M, Lenvik TR, Kodal B, Lenvik AJ, Hinderlie P, Bendzick LE, Schirm DK, Kaminski MF, McElmurry RT, Geller MA. et al. Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager. Cancer Immunol Res. 2020;8(9):1139–49. doi:10.1158/2326-6066.CIR-19-0837.
   PubMed Web of Science ®Google Scholar
• Siramshetty VB, Grishagin I, Nguyễn Ð-T, Peryea T, Skovpen Y, Stroganov O, Katzel D, Sheils T, Jadhav A, Mathé EA. et al. NCATS inxight drugs: a comprehensive and curated portal for translational research. Nucleic Acids Res. 2022;50(D1):D1307–16. doi:10.1093/nar/gkab918.
   PubMed Web of Science ®Google Scholar
• Abanades B, Wong WK, Boyles F, Georges G, Bujotzek A, Deane CM. ImmuneBuilder: deep-learning models for predicting the structures of immune proteins. Commun Biol. 2023;6:575. doi:10.1038/s42003-023-04927-7.
   PubMed Web of Science ®Google Scholar
• Zou H, Yuan R, Lai B, Dou Y, Wei L, Xu J. Antibody humanization via protein language model and neighbor retrieval. bioRxiv. 2023. doi:10.1101/2023.09.04.556278.
   Google Scholar
• Ruffolo JA, Chu L-S, Mahajan SP, Gray JJ. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat Commun. 2023;14(1):2389. doi:10.1038/s41467-023-38063-x.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A. et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–89. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Abanades B, Georges G, Bujotzek A, Deane CM, Xu J. Ablooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics. 2022;38(7):1877–80. doi:10.1093/bioinformatics/btac016.
   PubMed Web of Science ®Google Scholar
• Cohen T, Halfon M, Schneidman-Duhovny D. NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning. Front Immunol. 2022;13:958584. doi:10.3389/fimmu.2022.958584.
   PubMed Web of Science ®Google Scholar
• Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, Qin C, Žídek A, Nelson AWR, Bridgland A. et al. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577(7792):706–10. doi:10.1038/s41586-019-1923-7.
   PubMed Web of Science ®Google Scholar
• Schneider C, Raybould MIJ, Deane CM. SAbDab in the age of biotherapeutics: updates including SAbDab-nano, the nanobody structure tracker. Nucleic Acids Research. 2022;50(D1):D1368–72. doi:10.1093/nar/gkab1050.
   PubMed Web of Science ®Google Scholar
• Sankar K, Krystek SR, Carl SM, Day T, Maier JKX. AggScore: prediction of aggregation-prone regions in proteins based on the distribution of surface patches. Struct, Funct Bioinform. 2018;86(11):1147–56. doi:10.1002/prot.25594.
   PubMed Web of Science ®Google Scholar
• Myung Y, Pires DEV, Ascher DB, Martelli PL. CSM-AB: graph-based antibody–antigen binding affinity prediction and docking scoring function. Bioinformatics. 2022;38(4):1141–43. doi:10.1093/bioinformatics/btab762.
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco MS, Valdés-Tresanco ME, Jiménez-Gutiérrez DE, Moreno E. Structural modeling of nanobodies: a benchmark of state-of-the-art artificial intelligence programs. Molecules. 2023;28(10):3991. doi:10.3390/molecules28103991.
   PubMed Web of Science ®Google Scholar
• Huang C, Huang J, Zhu S, Tang T, Chen Y, Qian F. Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization. Chem Eng Sci. 2023;270:118521. doi:10.1016/j.ces.2023.118521.
   Web of Science ®Google Scholar
• Gaudreault F, Corbeil CR, Sulea T. Enhanced antibody-antigen structure prediction from molecular docking using AlphaFold2. Sci Rep. 2023;13(1):1507. doi:10.1038/s41598-023-42090-5.
   PubMed Web of Science ®Google Scholar
• Yin R, Pierce BG. Evaluation of AlphaFold antibody-antigen modeling with implications for improving predictive accuracy. bioRxiv. 2023. doi:10.1101/2023.07.05.547832.
   Google Scholar
• Liberis E, Veličković P, Sormanni P, Vendruscolo M, Liò P, Hancock J. Parapred: antibody paratope prediction using convolutional and recurrent neural networks. Bioinformat. 2018;34(17):2944–50. doi:10.1093/bioinformatics/bty305.
   Google Scholar
• Jespersen MC, Mahajan S, Peters B, Nielsen M, Marcatili P. Antibody specific B-cell epitope predictions: leveraging information from antibody-antigen protein complexes. Front Immunol. 2019;10:298. doi:10.3389/fimmu.2019.00298.
   PubMed Web of Science ®Google Scholar
• Collatz M, Mock F, Barth E, Hölzer M, Sachse K, Marz M, Lenore C. EpiDope: a deep neural network for linear B-cell epitope prediction. Bioinformat. 2021;37(4):448–55. doi:10.1093/bioinformatics/btaa773.
   Google Scholar
• McPartlon M, Xu J. Deep learning for flexible and site-specific protein docking and design. bioRxiv. 2023. doi:10.1101/2023.04.01.535079.
   Google Scholar
• Schneider C, Buchanan A, Taddese B, Deane CM, Valencia A. DLAB: deep learning methods for structure-based virtual screening of antibodies. Bioinformat. 2022;38(2):377–83. doi:10.1093/bioinformatics/btab660.
   Google Scholar
• Tam C, Kumar A, Zhang KYJ. NbX: machine learning-guided re-ranking of nanobody–antigen binding poses. Pharmaceut. 2021;14(10):968. doi:10.3390/ph14100968.
   Google Scholar
• Hummer AM, Schneider C, Chinery L, Deane CM. Investigating the volume and diversity of data needed for generalizable antibody-antigen ∆∆G prediction. bioRxiv. 2023. doi:10.1101/2023.05.17.541222v1.
   Google Scholar
• Hummer AM, Abanades B, Deane CM. Advances in computational structure-based antibody design. Curr Opin Struct Biol. 2022;74:102379. doi:10.1016/j.sbi.2022.102379.
   PubMed Web of Science ®Google Scholar
• Martinelli DD. Generative machine learning for de novo drug discovery: a systematic review. Comput Biol Med. 2022;145:105403. doi:10.1016/j.compbiomed.2022.105403.
   PubMed Web of Science ®Google Scholar
• Shuai RW, Ruffolo JA, Gray JJ. IgLM: infilling language modeling for antibody sequence design. Cell Syst. 2023;14(11):979–89.e4. doi:10.1016/j.cels.2023.10.001.
   PubMed Web of Science ®Google Scholar
• Watson JL, Juergens D, Bennett NR, Trippe BL, Yim J, Eisenach HE, Ahern W, Borst AJ, Ragotte RJ, Milles LF. et al. De Novo design of protein structure and function with RFdiffusion. Nature. 2023;620(7976):1089–100. doi:10.1038/s41586-023-06415-8.
   PubMed Web of Science ®Google Scholar
• Ferruz N, Schmidt S, Höcker B. ProtGPT2 is a deep unsupervised language model for protein design. Nat Commun. 2022;13(1):4348. doi:10.1038/s41467-022-32007-7.
   PubMed Web of Science ®Google Scholar
• Nijkamp E, Ruffolo JA, Weinstein EN, Naik N, Madani A. ProGen2: exploring the boundaries of protein language models. Cell Syst. 2023;14(11):968–78.e3. doi:10.1016/j.cels.2023.10.002.
   PubMed Web of Science ®Google Scholar
• Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W, Smetanin N, Verkuil R, Kabeli O, Shmueli Y. et al. Language models of protein sequences at the scale of evolution enable accurate structure prediction. bioRxiv. 2022. doi:10.1101/2022.07.20.500902.
   Google Scholar
• Elnaggar A, Heinzinger M, Dallago C, Rehawi G, Wang Y, Jones L, Gibbs T, Feher T, Angerer C, Steinegger M. et al. ProtTrans: toward understanding the language of life through self-supervised learning. IEEE Trans Pattern Anal Mach Intell. 2022;44(10):7112–27. doi:10.1109/TPAMI.2021.3095381.
   PubMed Web of Science ®Google Scholar
• Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformat. 2015;31(6):926–32. doi:10.1093/bioinformatics/btu739.
   Google Scholar
• Ruffolo JA, Gray JJ, Sulam J. Deciphering antibody affinity maturation with language models and weakly supervised learning. arXiv 2021. 2021. doi: 10.1093/2112.07782.
   Google Scholar
• Olsen TH, Moal IH, Deane CM, Lengauer T. AbLang: an antibody language model for completing antibody sequences. Bioinf Adv. 2022;2(1):vbac046. doi:10.1093/bioadv/vbac046.
   PubMedGoogle Scholar
• Hadsund JT, Satława T, Janusz B, Shan L, Zhou L, Röttger R, Krawczyk K. nanoBERT: a deep learning model for gene agnostic navigation of the nanobody mutational space. bioRxiv. 2024. doi:10.1101/2024.01.31.578143.
   Google Scholar
• Luo S, Su Y, Peng X, Wang S, Peng J, Ma J. Antigen-specific antibody design and optimization with diffusion-based generative models for protein structures. bioRxiv. 2022. doi:10.1101/2022.07.10.499510.
   Google Scholar
• Hie BL, Shanker VR, Xu D, Bruun TUJ, Weidenbacher PA, Tang S, Wu W, Pak JE, Kim PS. Efficient evolution of human antibodies from general protein language models. Nat Biotechnol. 2024;42(2):275–83. doi:10.1038/s41587-023-01763-2.
   PubMed Web of Science ®Google Scholar
• Bellamy H, Rehim AA, Orhobor OI, King R. Batched Bayesian optimization for drug design in noisy environments. J Chem Inf Model. 2022;62(17):3970–81. doi:10.1021/acs.jcim.2c00602.
   PubMedGoogle Scholar
• Seo S, Kwak MW, Kang E, Kim C, Park E, Kang TH, Kim J. Accelerating antibody design with active learning. bioRxiv. 2022. doi:10.1101/2022.09.12.507690.
   Google Scholar
• Khan A, Cowen-Rivers AI, Grosnit A, Deik D-G-X, Robert PA, Greiff V, Smorodina E, Rawat P, Akbar R, Dreczkowski K. et al. Toward real-world automated antibody design with combinatorial Bayesian optimization. Cell Rep Methods. 2023;3(1):100374. doi:10.1016/j.crmeth.2022.100374.
   PubMedGoogle Scholar
• Li L, Gupta E, Spaeth J, Shing L, Jaimes R, Engelhart E, Lopez R, Caceres RS, Bepler T, Walsh ME. Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries. Nat Commun. 2023;14(1):3454. doi:10.1038/s41467-023-39022-2.
   PubMed Web of Science ®Google Scholar
• Stanton S, Maddox W, Gruver N, Maffettone P, Delaney E, Greenside P, Wilson AG. Accelerating Bayesian optimization for biological sequence design with denoising autoencoders. Int Conf Mach Learn. 2022;20459–20478.
   Google Scholar
• Gruver N, Stanton S, Frey NC, Rudner TGJ, Hotzel I, Lafrance-Vanasse J, Rajpal A, Cho K, Wilson AG. Protein design with guided discrete diffusion. 2023. arXiv 2023. doi:10.1093/2305.20009.
   Google Scholar
• Sulea T. Humanization of camelid single-domain antibodies. Methods Mol Bio. 2022;2446:299–312.
   PubMedGoogle Scholar
• Marks C, Hummer AM, Chin M, Deane CM, Martelli PL. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformat. 2021;37(22):4041–47. doi:10.1093/bioinformatics/btab434.
   Google Scholar
• Prihoda D, Maamary J, Waight A, Juan V, Fayadat-Dilman L, Svozil D, Bitton DA. BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. Mabs-austin. 2022;14(1):2020203. doi:10.1080/19420862.2021.2020203.
   PubMed Web of Science ®Google Scholar
• Tennenhouse A, Khmelnitsky L, Khalaila R, Yeshaya N, Noronha A, Lindzen M, Makowski EK, Zaretsky I, Sirkis YF, Galon-Wolfenson Y. et al. Computational optimization of antibody humanness and stability by systematic energy-based ranking. Nat Biomed Eng. 2023;8(1):30–44. doi:10.1038/s41551-023-01079-1.
   PubMed Web of Science ®Google Scholar
• Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S, Loris R. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol. 2005;350(1):112–25. doi:10.1016/j.jmb.2005.04.050.
   PubMed Web of Science ®Google Scholar
• Abderrazek RB, Vincke C, Hmila I, Saerens D, Abidi N, Ayeb ME, Muyldermans S, Bouhaouala-Zahar B. Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of aahII scorpion toxin. Protein Eng Des Sel. 2011;24(9):727–35. doi:10.1093/protein/gzr037.
   PubMed Web of Science ®Google Scholar
• Ramon A, Saturnino A, Didi K, Greenig M, Sormanni P, Visentin C, Ricagno S, Xu X, Greenig M, Sormanni P. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nat Mach Intell. 2024;6(1):74–91. doi:10.1038/s42256-023-00778-3.
   Google Scholar